Allstate Corp Increases Stock Position in Intuitive Surgical, Inc. $ISRG

Allstate Corp lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2,510.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,159 shares of the medical equipment provider’s stock after purchasing an additional 12,655 shares during the quarter. Allstate Corp’s holdings in Intuitive Surgical were worth $5,885,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Tobam increased its holdings in shares of Intuitive Surgical by 666.7% in the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 40 shares during the period. Kilter Group LLC purchased a new stake in shares of Intuitive Surgical in the second quarter valued at about $27,000. Princeton Global Asset Management LLC acquired a new stake in shares of Intuitive Surgical during the second quarter worth about $30,000. Riggs Asset Managment Co. Inc. grew its holdings in shares of Intuitive Surgical by 84.2% during the second quarter. Riggs Asset Managment Co. Inc. now owns 70 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 32 shares during the last quarter. Finally, First Command Advisory Services Inc. grew its holdings in shares of Intuitive Surgical by 3,750.0% during the second quarter. First Command Advisory Services Inc. now owns 77 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 75 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Phase‑3 update on IS‑001 imaging drug — Intuitive advanced its Phase‑3 study aimed at reducing ureter injuries in robotic colorectal surgery, a safety-focused adjoint that could expand the company’s addressable offering and reinforce surgical‑safety differentiation. Intuitive Surgical Advances Phase 3 Imaging Drug
• Positive Sentiment: daVinci systems demand highlighted — Company commentary and industry coverage say system performance “exceeded expectations” and Intuitive is pushing for more placements, supporting procedure growth and recurring consumable revenue. Intuitive says daVinci systems ‘exceeded expectations,’ it wants more
• Positive Sentiment: Analyst support remains — At least some brokers (e.g., Bernstein) have reiterated buy ratings, signaling continued sell‑side conviction in ISRG’s long‑term growth profile despite near‑term noise. Bernstein Sticks to Their Buy Rating for Intuitive Surgical (ISRG)
• Positive Sentiment: Investor take: “buying the dip” narratives are emerging — Several bullish commentaries argue the pullback is an entry point given Intuitive’s wide moat, recurring consumables and procedure tailwinds. Intuitive Surgical: Buying The Dip On This Wide-Moat Compounder
• Neutral Sentiment: Analysts preparing for Q4 — Preview pieces outline the metrics (procedures, system placements, ASPs, margin drivers) that will matter when full Q4 results and guidance details arrive; these previews can amplify volatility around the print. Intuitive Surgical (ISRG) Q4 Earnings on the Horizon
• Neutral Sentiment: Brokerage commentary roundup — Coverage pieces remind investors that analyst ratings and model changes often move shares; they’re useful context but not a definitive signal by themselves. Brokers Suggest Investing in Intuitive Surgical (ISRG)
• Negative Sentiment: Preliminary Q4 revenue reaction — Although Intuitive reported strong preliminary Q4 and full‑year revenue growth, shares dipped as investors parsed procedure trends, margin dynamics and what management said about demand cadence. That disconnect between a beat and stock action is a key reason for the pullback. Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results
• Negative Sentiment: Softer 2026 outlook flagged — Company commentary and reporting point to a softer 2026 outlook that trimmed forward expectations, which is the primary negative driver behind today’s weakness. Intuitive Surgical Sets Softer 2026 Outlook
• Negative Sentiment: Market reaction analysis — Coverage asking “why did shares dive?” notes investors punished the stock for guidance/trajectory concerns despite the beat, illustrating that forward commentary and margin clarity matter more than one‑time beats. Intuitive Surgical Crushed Fourth-Quarter Forecasts. So Why Did Shares Dive?

Wall Street Analyst Weigh In

Several brokerages have issued reports on ISRG. Argus boosted their price objective on shares of Intuitive Surgical from $600.00 to $630.00 in a research note on Monday, October 27th. Leerink Partners raised their target price on shares of Intuitive Surgical from $593.00 to $600.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 22nd. Raymond James Financial set a $603.00 price target on shares of Intuitive Surgical and gave the stock an “outperform” rating in a research note on Wednesday, October 22nd. Daiwa Capital Markets increased their price target on shares of Intuitive Surgical from $510.00 to $550.00 and gave the stock an “outperform” rating in a report on Friday, October 24th. Finally, Wells Fargo & Company raised their price objective on shares of Intuitive Surgical from $600.00 to $654.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $622.17.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $535.00 on Monday. The company has a 50-day simple moving average of $566.32 and a 200-day simple moving average of $511.86. The company has a market cap of $191.79 billion, a PE ratio of 70.77, a price-to-earnings-growth ratio of 4.35 and a beta of 1.67. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.41. The business had revenue of $2.51 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.08%. The company’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period last year, the company earned $1.84 earnings per share. On average, analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, SVP Mark Brosius sold 464 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $548.49, for a total value of $254,499.36. Following the completion of the sale, the senior vice president directly owned 131 shares in the company, valued at approximately $71,852.19. The trade was a 77.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Myriam Curet sold 104 shares of the firm’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $559.90, for a total value of $58,229.60. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 114,007 shares of company stock valued at $63,533,844. Corporate insiders own 0.70% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.